ArticlePloS one2011
Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 74 citations in OpenAlex.
- An Open-Label, Comparative, Parallel Clinical Trial of the Safety, Pharmacokinetics and Immunogenicity of the Ustekinumab Biosimilar GNR-068 and the Originally Developed Ustekinumab as a Reference Drug After a Single Subcutaneous Administration in Healthy Male Volunteers.Antibodies (Basel, Switzerland) · 2026Article
- Type I interferons in tuberculosis pathogenesis and prevention.Trends in microbiology · 2026Review
- Oral and topical vitamin D treatment strategies in psoriasis.Skin health and disease · 2025Review
- The therapeutic efficacy of mesenchymal stem cells and their extracellular vesicles in the treatment of diverse skin diseases.Frontiers in immunology · 2025Review
- Psoriasis: Immunological and genetic blueprints driving pathogenesis and potential for personalized therapies.Iranian journal of basic medical sciences · 2025Review
- Deep analysis of skin molecular heterogeneities and their significance on the precise treatment of patients with psoriasis.Frontiers in immunology · 2024Article
- Drug- or Vaccine-Induced/Aggravated Psoriatic Arthritis: A Systematic Review.Dermatology and therapy · 2024Review
- Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea.JCI insight · 2023Article
- HypervirulentMicroorganisms · 2022Article
- Exploration of and insights into advanced topical nanocarrier systems for the treatment of psoriasis.Frontiers in medicine · 2022Review
- Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2021Review
- IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives.Vaccines · 2020Review
- IgE-mediated regulation of IL-10 and type I IFN enhances rhinovirus-induced Th2 differentiation by primary human monocytes.European journal of immunology · 2020Article
- Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma.Cancer immunology, immunotherapy : CII · 2020Review
- Comparison of Cytokine Expression in Paediatric and Adult Psoriatic Skin.Acta dermato-venereologica · 2020Article
- Spermidine Suppresses Inflammatory DC Function by Activating the FOXO3 Pathway and Counteracts Autoimmunity.iScience · 2020Article
- Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications.Cancers · 2019Article
- Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine.Cancer immunology, immunotherapy : CII · 2019Article
- Psoriasis Pathogenesis and Treatment.International journal of molecular sciences · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IFN-α exerts multiple effects leading to immune protection against pathogens and cancer as well to autoimmune reactions by acting on monocytes and dendritic cells. We analyzed the versatility of human monocytes conditioned by IFN-α towards dendritic cell differentiation (IFN-DC) in shaping the autologous T-helper response. Priming of naïve CD4 T cells with autologous IFN-DC in the presence of either SEA or anti-CD3, resulted, in addition to a prominent expansion of CXCR3+ IFN-γ-producing CD4 Th1 cells, in the emergence of two distinct subsets of IL-17-producing CD4 T cells: i) a predominant Th17 population selectively producing IL-17 and expressing CCR6; ii) a minor Th1/Th17 population, producing both IL-17 and IFN-γ. After phagocytosis of apoptotic cells, IFN-DC induced Th17 cell expansion and IL-17 release. Notably, the use of neutralizing antibodies revealed that IL-23 was an essential cytokine in mediating Th17 cell development by IFN-DC. The demonstration of the IFN-DC-induced expansion of both Th1 and Th17 cell populations reveals the intrinsic plasticity of these DC in orienting the immune response and provides a mechanistic link between IFN-α and the onset of autoimmune phenomena, which have been correlated with both IL-17 production and exposure to IFN-α.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.